Universities should work with new forms of commercial partner to take their own cancer drugs to market and drive down the ‘spiralling’ cost of new medicines, leading experts propose. A high-profile commentary warns that the price of cancer drugs is...
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2kTbaJn
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Objective A systematic review and meta-analysis to investigate the impact of electronic nicotine delivery systems (ENDS) and/or electronic n...
-
Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers British Journal of Cancer 116, 1425 (23 May 2017). ...
-
Publication date: April 2017 Source: European Journal of Cancer, Volume 75 Author(s): A. Ieni, G. Angelico, P. Zeppa, G. Tuccari fro...
-
Publication date: October 2017 Source: International Journal of Biological Macromolecules, Volume 103 Author(s): Shehwaz Anwar, Hina Youn...
-
Precision design of nanomedicines to restore gemcitabine chemosensitivity for personalized pancreatic ductal adenocarcinoma treatment. ...
-
Abstract Maternal obesity is associated with large-for-gestational-age (LGA) neonates and programming of obesity-related cardiovascular d...
-
Publication date: 20 March 2017 Source: Gene, Volume 605 Author(s): Hicham El Hadi, Imane Abdellaoui-Maane, Denise Kottwitz, Manal El Amra...
-
Related Articles Modulation of the Tumor Microenvironment by Epstein-Barr virus Latent Membrane Protein-1 in Nasopharyngeal Carcinoma....
-
Publication date: Available online 10 March 2018 Source: Radiotherapy and Oncology Author(s): Igor Shuryak, Eric J. Hall, David J. Bre...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου